Abstract
Pralmorelin [GPA 748, GHRP 2, growth hormone-releasing peptide 2, KP-102 D, KP 102 LN] is an orally active, synthetic growth hormone-releasing peptide from a series of compounds that were developed by Polygen in Germany and Tulane University in the US.
Researchers at Tulane University led by Dr Cyril Bowers synthesised a series of small highly active peptides ranging in size from 3–5 amino acids or partial peptides that were suitable for a variety of administration formats (subcutaneous, buccal, oral, depot). These peptides mimic the actions of ghrelin, a 28 amino acid octanoyl peptide that regulates the release of growth hormone (GH), and may play an important role in bone and muscle growth, food intake and possibly improve recovery from injury.
The use of pralmorelin as a diagnostic agent for GH deficiency is based on its ability to markedly increase plasma levels of GH in healthy subjects irrespectively of gender, obesity or age. However, in patients with GH deficiency, the effect of pralmorelin on GH levels is significantly lower compared with healthy controls. Analysis of the receiver-operating characteristics curve provided the cut-off threshold value for the GH peak of 15.0 μg/L for the identification of patients with GH deficiency from those of healthy controls.
Kaken acquired worldwide manufacturing and marketing rights to pralmorelin, and then sublicensed it to Wyeth (formerly American Home Products) for the US and Canada. Kaken retains rights to pralmorelin in Japan. On 11 March 2002 American Home Products changed its name and the names of its subsidiaries Wyeth-Ayerst and Wyeth Lederle to Wyeth.
Kaken also granted exclusive sublicense options in Africa, Australia, Europe, Latin America and New Zealand to unspecified partners.
Pralmorelin as KP-102 D [KP-102D] is currently awaiting approval in Japan as a diagnostic agent for hypothalamo-pituitary function. It is planned to be launched in Japan for this indication in 2004. Pralmorelin is also undergoing phase II clinical trials with Kaken in Japan for short stature (pituitary dwarfism) as KP-102 LN [KP-102LN]. Its launch for the treatment of short stature is planned for 2009 (Kaken, Annual Report 2003).
The agent was undergoing phase II trials in the US for the treatment of GH deficiency with Wyeth; however, it appears that its development was discontinued.
Tulane University was granted a US Patent (6,468,974 issued in October 2002), as well as patent protection in Europe and other countries for a series of synthesised GH-releasing peptides.
Similar content being viewed by others
References
Jordan RA, Kagan N, Scatina J. Metabolism and excretion of a growth hormone releasing peptide, GPA-748 or GHRP-2, in rats and monkeys following intravenous, subcutaneous and oral administration. 7th North American ISSX Meeting 10: 340, 20 Oct 1996
Pihoker C, Badger TM, Reynolds GA. Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature. Journal of Endocrinology 155: 79–86, Oct 1997
Chihara K, Iida K, Okimura Y, et al. Usefullness of growth hormone releasing peptide-2 (KP-102) stimulation test for diagnosis of severe growth hormone deficiency. 84th Annual Meeting of the Endocrine Society: 33, 19 Jun 2002
Tiulpakov AN, Brook CGD, Pringle PJ. GH response to intravenous bolus infusions of GH releasing hormone, GH releasing peptide 2 and combination of GHRH and GHRP-2. European Journal of Endocrinology 130 (Suppl. 2): 190, Jun 1994
Pihoker C, Kearns GL, French D. Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children. Journal of Clinical Endocrinology and Metabolism 83: 1168–1172, Apr 1998
Gondo RG, Aguiar-Oliveira MH, Hayashida CY, et al. Growth hormone-releasing peptide-2 stimulates GH secretion in GH-deficient patients with mutated GH-releasing hormone receptor. Journal of Clinical Endocrinology and Metabolism 86: 3279–3283, Jul 2001
Meric V, Cassorla F, Bowers CY, et al. Changes in appetite and body weight in response to long-term oral administration of the ghrelin agonist GHRP-2 in GH-deficient children. Pediatric Research 49: 129, Part 2, Jun 2001
Author information
Consortia
Rights and permissions
About this article
Cite this article
Adis Editorial. Pralmorelin. Drugs R D 5, 236–239 (2004). https://doi.org/10.2165/00126839-200405040-00011
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200405040-00011